A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective
• To assess the dose response relationship between RGLS4326 and ADPKD biomarkers
Secondary Objectives
- To characterize the pharmacokinetic (PK) properties of RGLS4326 in plasma and urine
- To assess the safety and tolerability of RGLS4326